During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular BiologyT series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results.
Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.
Rezensionen / Stimmen
From the reviews of the second edition:
"Text thoroughly presented the subject of antithrombotic and anticoagulant therapy in great depth and with complete review of the subject. In 13 chapters outstanding experts in their field have provided the cardiovascular specialist, hematologist, and pathologist with a thorough updating of the pharmacology of antithrombotic and anticoagulant therapy. . text should provide anyone working in the field of cardiovascular medicine or surgery and in hematology or pathology with a way to keep current with developments in the field of cardiovascular pharmacology. We recommend it highly." (Harry L. Messmore and William H. Wehrmacher, Clinical and Applied Thrombosis/Hemostasis, November, 2010)
"Recent advances in testing and use of anticoagulants, antiplatelets, and thrombolytics and the essentials of efficacy testing, novel direct thrombin inhibitors, use of naturally-derived products, and pharmacogenomics in thrombosis. . The book is likely to be of interest to both academic scientists and practitioners interested in the treatment of patients with thrombosis. . This is very likely to make it onto the shelf in our laboratory, in particular as a reference for current advances in antithrombotics and thrombolytics." (James P. Luyendyk, Doody's Review Service, December, 2010)
Reihe
Auflage
Sprache
Verlagsort
Zielgruppe
Für Beruf und Forschung
Professional/practitioner
Editions-Typ
Produkt-Hinweis
Fadenheftung
Gewebe-Einband
Illustrationen
Maße
Höhe: 266 mm
Breite: 187 mm
Dicke: 28 mm
Gewicht
ISBN-13
978-1-60761-802-7 (9781607618027)
DOI
10.1007/978-1-60761-803-4
Schweitzer Klassifikation
In Vitro Methods of Evaluating Antithrombotics and Thrombolytics.- In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics.- Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond.- Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia.- Novel Anticoagulant Therapy: Principle and Practice.- Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban.- Antiplatelet Therapies: Drug Interactions in the Management of Vascular Disorders.- Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist.- Antithrombotic Effects of Naturally Derived Products on Coagulation and Platelet Function.- Assessment of Anti-Metastatic Effects of Anticoagulant and Antiplatelet Agents Using Animal Models of Experimental Lung Metastasis.- Adhesion Molecules: Potential Therapeutic and Diagnostic Implications.- Pharmacogenomics in Thrombosis.- Diagnosis and Management of Sickle Cell Disorders.
